Rituxan Adds Third NHL Indication In 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
The Genentech/Biogen Idec oncologic, first approved in 1997, is now also approved for first-line with CVP and ongoing treatment of stable disease.
You may also be interested in...
Dr. Reddy's Launches Rituxan Generic
Dr. Reddy's Laboratories launched the first follow-on biologic of the non-Hodgkin's lymphoma treatment rituximab on April 30, the company announced
Dr. Reddy’s Launches Rituxan Generic
Indian company plans to market Reditux in India at half the cost of Genentech/Biogen Idec’s Rituxan (rituximab).
Dr. Reddy’s Launches Rituxan Generic
Indian company plans to market Reditux in India at half the cost of Genentech/Biogen Idec’s Rituxan (rituximab).